GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma <i>via</i> modulation of lysosomal functionsSonia Brun(Genoscience Pharma (France)), Philippe Halfon(Genoscience Pharma (France))AutophagyNovember 5, 202110.1080/15548627.2021.1988357Cited by 84SaveCiteExport RISWatch citationsRelated PapersGNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition|Viruses|2022|19